NxStage Medical Stock Price, News & Analysis (NASDAQ:NXTM)

$24.13 -0.25 (-1.03 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$24.13
Today's Range$24.03 - $24.54
52-Week Range$20.45 - $30.80
Volume646,500 shs
Average Volume616,675 shs
Market Capitalization$1.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.08

About NxStage Medical (NASDAQ:NXTM)

NxStage Medical logoNxStage Medical, Inc. is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets. The In-Center segment includes revenues from the sale of blood tubing sets and needles for hemodialysis, primarily for the treatment of end-stage renal disease patients at dialysis clinics, and needles for apheresis. It markets extracorporeal disposable products under the Medisystems brand. The Services segment includes revenues from dialysis services provided to patients at its NxStage Kidney Care dialysis centers. Its product offerings include Home Dialysis, Next-Generation Hemodialysis System, Critical Care, Next-Generation Critical Care System and In-Center.

Receive NXTM News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Imaging Systems
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NXTM
CUSIP67072V10
Phone978-687-4700

Debt

Debt-to-Equity RatioN/A
Current Ratio3.23%
Quick Ratio2.19%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$393.94 million
Price / Sales4.06
Cash Flow$0.28 per share
Price / Cash86.72
Book Value$3.21 per share
Price / Book7.52

Profitability

Trailing EPS($0.07)
Net Income$-4,770,000.00
Net Margins-3.68%
Return on Equity-6.80%
Return on Assets-4.45%

Miscellaneous

Employees3,400
Outstanding Shares66,320,000

NxStage Medical (NASDAQ:NXTM) Frequently Asked Questions

What is NxStage Medical's stock symbol?

NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM."

How were NxStage Medical's earnings last quarter?

NxStage Medical, Inc. (NASDAQ:NXTM) issued its quarterly earnings results on Monday, August, 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.00. The medical device company earned $92.20 million during the quarter, compared to analyst estimates of $96.47 million. NxStage Medical had a negative return on equity of 6.80% and a negative net margin of 3.68%. The firm's revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.03) EPS. View NxStage Medical's Earnings History.

Where is NxStage Medical's stock going? Where will NxStage Medical's stock price be in 2018?

8 brokerages have issued 1-year target prices for NxStage Medical's stock. Their forecasts range from $27.00 to $32.00. On average, they anticipate NxStage Medical's stock price to reach $29.86 in the next twelve months. View Analyst Ratings for NxStage Medical.

What are Wall Street analysts saying about NxStage Medical stock?

Here are some recent quotes from research analysts about NxStage Medical stock:

  • 1. According to Zacks Investment Research, "NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. " (2/13/2018)
  • 2. Northland Securities analysts commented, "We continue to move our PD program forward at an impressive pace…We continue to firmly believe that by keeping our regulatory timelines and pathway confidential, we’re protecting a significant value opportunity. Let me be clear, we both have the opportunity to do great things for patients, bringing new technology to the market that makes PD easier and better." (8/7/2017)

Who are some of NxStage Medical's key competitors?

Who are NxStage Medical's key executives?

NxStage Medical's management team includes the folowing people:

  • Robert G. Funari, Independent Chairman of the Board (Age 69)
  • Joseph E. Turk Jr., President (Age 49)
  • Jeffrey H. Burbank, Chief Executive Officer, Director (Age 54)
  • Matthew W. Towse CPA, Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer (Age 54)
  • Robert S. Brown, President of NxStage Kidney Care (Age 58)
  • Winifred L. Swan J.D., Senior Vice President, General Counsel (Age 52)
  • Heyward R. Donigan, Independent Director (Age 56)
  • Daniel A. Giannini CPA, , Independent Director (Age 67)
  • Earl R. Lewis, Independent Director (Age 73)
  • Jean K. Mixer, Independent Director (Age 50)

Who owns NxStage Medical stock?

NxStage Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.64%), Alpine Associates Management Inc. (6.09%), Deutsche Bank AG (2.91%), Pennant Capital Management LLC (2.65%), State of Wisconsin Investment Board (1.60%) and Goldman Sachs Group Inc. (1.43%). Company insiders that own NxStage Medical stock include Barry M Straube, Craig W Moore, Daniel A Giannini, Jeffrey H Burbank, Joseph E Turk Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Institutional Ownership Trends for NxStage Medical.

Who sold NxStage Medical stock? Who is selling NxStage Medical stock?

NxStage Medical's stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, OppenheimerFunds Inc., Deutsche Bank AG, Goldman Sachs Group Inc., Jefferies Group LLC, Two Sigma Advisers LP, Alliancebernstein L.P. and ARP Americas LP. Company insiders that have sold NxStage Medical company stock in the last year include Craig W Moore, Jeffrey H Burbank, Joseph E Turk Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Insider Buying and Selling for NxStage Medical.

Who bought NxStage Medical stock? Who is buying NxStage Medical stock?

NxStage Medical's stock was acquired by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, Tamarack Advisers LP, EnTrustPermal Partners Offshore LP, Senzar Asset Management LLC, K2 Principal Fund L.P., Renaissance Technologies LLC, Pennant Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for NxStage Medical.

How do I buy NxStage Medical stock?

Shares of NxStage Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NxStage Medical's stock price today?

One share of NxStage Medical stock can currently be purchased for approximately $24.13.

How big of a company is NxStage Medical?

NxStage Medical has a market capitalization of $1.60 billion and generates $393.94 million in revenue each year. The medical device company earns $-4,770,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. NxStage Medical employs 3,400 workers across the globe.

How can I contact NxStage Medical?

NxStage Medical's mailing address is 350 MERRIMACK STREET, LAWRENCE MA, 01843. The medical device company can be reached via phone at 978-687-4700 or via email at [email protected]


MarketBeat Community Rating for NxStage Medical (NXTM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  431
MarketBeat's community ratings are surveys of what our community members think about NxStage Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NxStage Medical (NASDAQ:NXTM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.86$29.86$29.86$29.86
Price Target Upside: 15.48% upside15.48% upside15.48% upside2.57% upside

NxStage Medical (NASDAQ:NXTM) Consensus Price Target History

Price Target History for NxStage Medical (NASDAQ:NXTM)

NxStage Medical (NASDAQ:NXTM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017Northland SecuritiesReiterated RatingHold$30.00N/AView Rating Details
10/17/2017Canaccord GenuityReiterated RatingHold$30.00N/AView Rating Details
8/22/2017Leerink SwannDowngradeOutperform -> Market Perform$28.00 -> $30.00HighView Rating Details
8/11/2017BTIG ResearchDowngradeBuy -> NeutralLowView Rating Details
8/9/2017StephensDowngradeOverweight -> Equal Weight$33.00 -> $30.00LowView Rating Details
8/8/2017Jefferies GroupDowngradeBuy -> Hold$33.00 -> $30.00MediumView Rating Details
8/7/2017William BlairDowngradeOutperform -> Market PerformMediumView Rating Details
8/7/2017Craig HallumDowngradeBuy -> HoldHighView Rating Details
6/3/2016Piper Jaffray CompaniesReiterated RatingBuy$21.00N/AView Rating Details
5/5/2016Wells Fargo & CoReiterated RatingSellN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

NxStage Medical (NASDAQ:NXTM) Earnings History and Estimates Chart

Earnings by Quarter for NxStage Medical (NASDAQ:NXTM)

NxStage Medical (NASDAQ NXTM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.03)($0.03)$96.47 million$92.20 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.03)($0.02)$95.31 million$96.83 millionViewListenView Earnings Details
2/28/2017Q416($0.02)($0.02)$91.82 million$93.01 millionViewListenView Earnings Details
8/4/2016Q216($0.04)($0.03)$89.44 million$92.20 millionViewN/AView Earnings Details
5/4/2016Q116($0.05)($0.02)$88.40 million$89.20 millionViewListenView Earnings Details
2/10/2016Q415($0.04)($0.04)$86.83 million$89.80 millionViewListenView Earnings Details
11/3/2015Q315($0.08)($0.03)$82.06 million$86.50 millionViewN/AView Earnings Details
8/6/2015Q215($0.10)($0.08)$79.89 million$80.30 millionViewListenView Earnings Details
5/6/2015Q115($0.11)($0.09)$77.92 million$79.50 millionViewListenView Earnings Details
2/26/2015Q414($0.10)($0.08)$75.75 million$79.90 millionViewListenView Earnings Details
11/6/2014Q3($0.13)($0.07)$71.83 million$75.30 millionViewN/AView Earnings Details
8/7/2014Q214($0.11)($0.12)$70.52 million$74.10 millionViewN/AView Earnings Details
5/8/2014Q114($0.11)($0.09)$69.44 million$72.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.08)$67.66 million$69.40 millionViewN/AView Earnings Details
11/7/2013Q313$0.22($0.08)$124.03 million$66.90 millionViewListenView Earnings Details
7/25/2013Q2 2013($0.07)($0.06)$64.66 million$65.50 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.08)($0.08)$61.14 million$61.60 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.05)($0.04)$63.54 million$65.00 millionViewN/AView Earnings Details
11/8/2012Q312($0.06)($0.04)$60.90 million$61.00 millionViewN/AView Earnings Details
8/8/2012($0.09)($0.09)ViewN/AView Earnings Details
5/8/2012($0.09)($0.09)ViewN/AView Earnings Details
2/29/2012($0.09)($0.08)ViewN/AView Earnings Details
11/3/2011($0.10)($0.10)ViewN/AView Earnings Details
8/3/2011($0.10)($0.10)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.12)($0.11)ViewN/AView Earnings Details
2/17/2011Q4 2010($0.14)($0.13)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.16)($0.17)ViewN/AView Earnings Details
7/23/2010Q2 2010($0.18)($0.17)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.20)($0.19)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.20)($0.19)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.23)($0.22)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.26)($0.27)ViewN/AView Earnings Details
5/8/2009Q1 2009($0.28)($0.26)ViewN/AView Earnings Details
3/12/2009Q4 2008($0.28)($0.26)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.32)($0.29)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.34)($0.32)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.39)($0.38)ViewN/AView Earnings Details
2/12/2008Q4 2007($0.33)($0.39)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

NxStage Medical (NASDAQ:NXTM) Earnings Estimates

2018 EPS Consensus Estimate: $0.11
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.01$0.02$0.02
Q2 20182$0.01$0.01$0.01
Q3 20182$0.02$0.05$0.04
Q4 20182$0.04$0.05$0.05
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for NxStage Medical (NASDAQ:NXTM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

NxStage Medical (NASDAQ NXTM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 83.23%
Insider Trades by Quarter for NxStage Medical (NASDAQ:NXTM)
Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

NxStage Medical (NASDAQ NXTM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2018Winifred L SwanSVPSell3,500$24.48$85,680.00View SEC Filing  
1/16/2018Winifred L SwanSVPSell3,500$24.88$87,080.0013,770View SEC Filing  
12/20/2017Winifred L SwanSVPSell3,500$25.35$88,725.0014,270View SEC Filing  
11/15/2017Winifred L SwanSVPSell3,500$25.73$90,055.00View SEC Filing  
10/20/2017Winifred L SwanSVPSell3,500$27.50$96,250.0015,270View SEC Filing  
10/4/2017Joseph E Turk JrPresidentSell1,000$27.56$27,560.00View SEC Filing  
9/20/2017Matthew W TowseSVPSell4,300$27.27$117,261.0028,721View SEC Filing  
9/5/2017Joseph E Turk JrPresidentSell1,000$27.95$27,950.0073,903View SEC Filing  
8/21/2017Matthew W TowseSVPSell4,300$29.22$125,646.0028,721View SEC Filing  
8/15/2017Winifred L SwanSVPSell3,500$29.21$102,235.0016,270View SEC Filing  
8/10/2017Joseph E Turk JrPresidentSell1,000$29.26$29,260.0074,903View SEC Filing  
8/7/2017Joseph E Turk JrPresidentSell24,000$29.64$711,360.0082,903View SEC Filing  
8/3/2017Joseph E Turk JrPresidentSell7,000$22.98$160,860.0082,903View SEC Filing  
7/20/2017Matthew W TowseSVPSell4,300$24.16$103,888.0028,721View SEC Filing  
7/5/2017Joseph E Turk JrPresidentSell1,000$25.19$25,190.0075,903View SEC Filing  
6/20/2017Matthew W TowseSVPSell4,300$23.29$100,147.0029,637View SEC Filing  
6/15/2017Winifred L SwanSVPSell3,500$23.14$80,990.0017,270View SEC Filing  
6/14/2017Joseph E Turk JrPresidentSell1,000$23.74$23,740.0075,903View SEC Filing  
5/22/2017Matthew W TowseSVPSell4,300$21.36$91,848.0029,637View SEC Filing  
5/15/2017Winifred L SwanSVPSell3,500$21.94$76,790.0017,770View SEC Filing  
5/10/2017Joseph E Turk JrPresidentSell250$23.59$5,897.5078,153View SEC Filing  
5/3/2017Joseph E Turk JrPresidentSell1,000$29.95$29,950.0077,903View SEC Filing  
4/20/2017Jeffrey H BurbankCEOSell3,000$27.28$81,840.00939,086View SEC Filing  
4/20/2017Matthew W TowseSVPSell4,300$27.28$117,304.0029,637View SEC Filing  
4/19/2017Jeffrey H BurbankCEOSell3,000$26.65$79,950.00942,086View SEC Filing  
4/13/2017Joseph E Turk JrPresidentSell1,000$26.10$26,100.0078,903View SEC Filing  
4/3/2017Robert S BrownInsiderSell14,397$26.60$382,960.2028,003View SEC Filing  
3/22/2017Jeffrey H BurbankCEOSell3,000$27.42$82,260.00945,086View SEC Filing  
3/21/2017Jeffrey H BurbankCEOSell3,000$27.72$83,160.00948,086View SEC Filing  
3/20/2017Winifred L SwanSVPSell15,723$27.66$434,898.1830,993View SEC Filing  
3/16/2017Craig W MooreDirectorSell1,000$27.93$27,930.0094,943View SEC Filing  
3/8/2017Joseph E Turk JrPresidentSell1,000$27.53$27,530.0079,903View SEC Filing  
3/7/2017Robert S BrownInsiderSell20,000$27.75$555,000.0036,086View SEC Filing  
3/6/2017Robert S BrownInsiderSell6,390$28.01$178,983.9027,062View SEC Filing  
2/23/2017Jeffrey H BurbankCEOSell7,500$28.97$217,275.00936,249View SEC Filing  
2/22/2017Jeffrey H BurbankCEOSell7,500$29.01$217,575.00943,749View SEC Filing  
2/17/2017Joseph E Turk JrPresidentSell6,000$29.66$177,960.0075,280View SEC Filing  
2/15/2017Winifred L SwanSVPSell16,049$28.01$449,532.4926,522View SEC Filing  
2/14/2017Robert S BrownInsiderSell2,448$28.28$69,229.4417,315View SEC Filing  
2/10/2017Joseph E Turk JrPresidentSell3,500$28.36$99,260.0069,280View SEC Filing  
2/8/2017Robert S BrownInsiderSell3,054$27.61$84,320.9419,763View SEC Filing  
2/7/2017Robert S BrownInsiderSell3,117$27.54$85,842.1822,817View SEC Filing  
2/6/2017Robert S BrownInsiderSell16,283$26.87$437,524.2142,217View SEC Filing  
2/2/2017Joseph E Turk JrPresidentSell15,669$26.19$410,371.1172,949View SEC Filing  
2/2/2017Robert S BrownInsiderSell37,347$26.68$996,417.9653,564View SEC Filing  
1/26/2017Robert S BrownInsiderSell42,000$26.05$1,094,100.0055,564View SEC Filing  
1/23/2017Robert S BrownInsiderSell21,615$26.20$566,313.0040,764View SEC Filing  
1/20/2017Matthew W TowseSVPSell4,300$26.19$112,617.0023,041View SEC Filing  
1/18/2017Jeffrey H BurbankCEOSell7,500$27.63$207,225.00867,616View SEC Filing  
1/18/2017Robert S BrownInsiderSell8,183$27.58$225,687.1447,179View SEC Filing  
1/17/2017Jeffrey H BurbankCEOSell7,500$27.52$206,400.00875,116View SEC Filing  
1/17/2017Robert S BrownInsiderSell10,805$27.72$299,514.6055,362View SEC Filing  
1/13/2017Joseph E Turk JrPresidentSell7,500$28.00$210,000.0070,280View SEC Filing  
1/11/2017Joseph E Turk JrPresidentSell1,000$27.77$27,770.0077,780View SEC Filing  
12/20/2016Matthew W TowseSVPSell4,300$25.55$109,865.0023,041View SEC Filing  
12/15/2016Winifred L SwanSVPSell3,500$25.91$90,685.0014,973View SEC Filing  
12/14/2016Jeffrey H BurbankCEOSell7,500$25.68$192,600.00882,616View SEC Filing  
12/13/2016Jeffrey H BurbankCEOSell7,500$25.42$190,650.00890,116View SEC Filing  
12/13/2016Joseph E Turk JrPresidentSell1,000$25.42$25,420.0078,780View SEC Filing  
11/28/2016Joseph E Turk JrPresidentSell12,169$26.01$316,515.6986,780View SEC Filing  
11/23/2016Jeffrey H BurbankCEOSell7,500$24.01$180,075.00897,616View SEC Filing  
11/22/2016Jeffrey H BurbankCEOSell7,500$25.51$191,325.00905,116View SEC Filing  
11/22/2016Winifred L SwanSVPSell3,000$25.51$76,530.0014,973View SEC Filing  
11/21/2016Daniel A GianniniDirectorSell6,449$25.96$167,416.0463,193View SEC Filing  
11/21/2016Matthew W TowseSVPSell4,300$26.23$112,789.0023,041View SEC Filing  
11/17/2016Joseph E Turk JrPresidentSell1,000$25.97$25,970.0079,780View SEC Filing  
11/16/2016Joseph E Turk JrPresidentSell22,500$26.26$590,850.0080,780View SEC Filing  
9/14/2016Craig W MooreDirectorSell3,000$23.31$69,930.0090,739View SEC Filing  
5/12/2016Joseph E Turk JrPresidentSell1,500$17.89$26,835.00103,280View SEC Filing  
5/10/2016Joseph E Turk JrPresidentSell1,057$18.00$19,026.00105,837View SEC Filing  
4/21/2016Joseph E Turk JrPresidentSell2,000$15.73$31,460.00104,780View SEC Filing  
4/14/2016Winifred L SwanSVPSell6,260$16.40$102,664.0015,734View SEC Filing  
4/5/2016Joseph E Turk JrPresidentSell2,500$15.05$37,625.00109,280View SEC Filing  
3/22/2016Joseph E Turk JrPresidentSell2,000$14.34$28,680.00108,280View SEC Filing  
3/14/2016Winifred L SwanSVPSell620$15.69$9,727.8018,234View SEC Filing  
3/10/2016Joseph E Turk JrPresidentSell2,500$15.58$38,950.00112,780View SEC Filing  
2/24/2016Barry M StraubeDirectorBuy1,500$14.20$21,300.001,500View SEC Filing  
2/24/2016Joseph E Turk JrPresidentSell2,992$14.12$42,247.04108,155View SEC Filing  
2/16/2016Winifred L. SwanSVPSell2,500$14.07$35,175.0012,439View SEC Filing  
2/12/2016Earl R. LewisDirectorBuy21,000$14.63$307,230.0088,145View SEC Filing  
2/10/2016Joseph E. Turk, Jr.PresidentSell991$16.25$16,103.75107,163View SEC Filing  
2/9/2016Joseph E. Turk, Jr.PresidentSell2,500$16.88$42,200.00107,163View SEC Filing  
2/4/2016Joseph E. Turk, Jr.PresidentSell991$19.60$19,423.60108,663View SEC Filing  
1/20/2016Joseph E Turk JrPresidentSell2,000$18.75$37,500.00108,663View SEC Filing  
1/14/2016Winifred L. SwanSVPSell620$19.04$11,804.8014,319View SEC Filing  
1/11/2016Matthew W. TowseSVPSell3,472$20.40$70,828.8012,947View SEC Filing  
1/8/2016Joseph E. Turk, Jr.PresidentSell1,500$21.03$31,545.00110,663View SEC Filing  
1/7/2016Joseph E. Turk, Jr.PresidentSell3,713$20.78$77,156.14110,663View SEC Filing  
12/22/2015Joseph E. Turk, Jr.PresidentSell5,000$20.92$104,600.00100,963View SEC Filing  
12/16/2015Joseph E. Turk, Jr.PresidentSell800$19.99$15,992.00102,963View SEC Filing  
12/15/2015Matthew W. TowseSVPSell2,863$19.51$55,857.1312,947View SEC Filing  
12/14/2015Winifred L. SwanSVPSell2,500$18.90$47,250.0014,319View SEC Filing  
12/10/2015Jeffrey H. BurbankCEOSell9,274$18.94$175,649.56876,756View SEC Filing  
12/8/2015Joseph E. Turk, Jr.PresidentSell2,913$19.38$56,453.94102,963View SEC Filing  
11/20/2015Craig W MooreDirectorSell1,000$20.00$20,000.0092,046View SEC Filing  
11/19/2015Joseph E Turk JrPresidentSell2,000$19.65$39,300.00104,463View SEC Filing  
11/18/2015Craig W MooreDirectorSell4,000$19.60$78,400.0093,046View SEC Filing  
11/16/2015Winifred L. SwanSVPSell2,500$19.65$49,125.0016,199View SEC Filing  
11/12/2015Joseph E. Turk, Jr.PresidentSell4,055$20.44$82,884.20106,463View SEC Filing  
11/10/2015Jeffrey H. BurbankCEOSell10,000$20.75$207,500.00876,756View SEC Filing  
11/10/2015Joseph E. Turk, Jr.PresidentSell7,500$21.03$157,725.00107,963View SEC Filing  
11/10/2015Matthew W. TowseSVPSell2,863$20.32$58,176.1612,947View SEC Filing  
11/9/2015Daniel A GianniniDirectorSell6,593$20.30$133,837.9063,780View SEC Filing  
11/9/2015Jeffrey H. BurbankCEOSell10,000$20.32$203,200.00876,756View SEC Filing  
11/4/2015Joseph E. Turk, Jr.PresidentSell4,826$19.62$94,686.12107,963View SEC Filing  
11/4/2015Matthew W. TowseSVPSell8,591$19.50$167,524.5012,947View SEC Filing  
11/3/2015Robert S. BrowninsiderSell44,400$19.00$843,600.0059,777View SEC Filing  
10/20/2015Joseph E. Turk, Jr.PresidentSell2,000$15.80$31,600.00107,963View SEC Filing  
10/16/2015Jeffrey H. BurbankCEOSell10,000$15.59$155,900.00876,756View SEC Filing  
10/15/2015Jeffrey H. BurbankCEOSell10,000$14.98$149,800.00876,756View SEC Filing  
10/14/2015Winifred L. SwanSVPSell2,500$15.46$38,650.0018,079View SEC Filing  
10/8/2015Joseph E. Turk, Jr.PresidentSell2,839$15.42$43,777.38104,163View SEC Filing  
9/24/2015Joseph E Turk JrPresidentSell2,000$17.26$34,520.00105,663View SEC Filing  
9/17/2015Jeffrey H. BurbankCEOSell10,000$16.18$161,800.00876,756View SEC Filing  
9/16/2015Jeffrey H. BurbankCEOSell10,000$15.99$159,900.00876,756View SEC Filing  
9/15/2015Craig W MooreDirectorSell1,000$16.00$16,000.0097,046View SEC Filing  
9/14/2015Winifred L. SwanSVPSell2,500$16.01$40,025.0019,959View SEC Filing  
9/9/2015Joseph E. Turk, Jr.PresidentSell2,839$16.54$46,957.06107,663View SEC Filing  
8/25/2015Joseph E Turk JrPresidentSell2,000$18.25$36,500.00109,163View SEC Filing  
8/17/2015Robert S BrownInsiderSell10,825$18.30$198,097.50View SEC Filing  
8/14/2015Winifred L SwanSVPSell2,500$18.14$45,350.00View SEC Filing  
8/13/2015Jeffrey H BurbankCEOSell10,000$18.31$183,100.00View SEC Filing  
8/12/2015Jeffrey H BurbankCEOSell10,000$18.03$180,300.00View SEC Filing  
8/12/2015Joseph E Turk JrPresidentSell3,252$17.74$57,690.48View SEC Filing  
7/22/2015Joseph E Turk JrPresidentSell2,000$13.86$27,720.00View SEC Filing  
7/14/2015Winifred L SwanSVPSell2,500$14.71$36,775.00View SEC Filing  
6/23/2015Joseph E Turk JrPresidentSell2,000$15.36$30,720.00View SEC Filing  
6/18/2015Jeffrey H BurbankCEOSell20,000$15.56$311,200.00View SEC Filing  
6/15/2015Winifred L SwanSVPSell2,500$15.48$38,700.00View SEC Filing  
6/10/2015Joseph E Turk JrPresidentSell2,839$16.00$45,424.00View SEC Filing  
5/18/2015Winifred L SwanSVPSell2,500$16.65$41,625.00View SEC Filing  
5/12/2015Jeffrey H BurbankCEOSell10,000$16.44$164,400.00View SEC Filing  
4/21/2015Joseph E Turk JrPresidentSell1,950$18.40$35,880.00View SEC Filing  
4/17/2015Jeffrey H BurbankCEOSell10,000$18.08$180,800.00View SEC Filing  
4/16/2015Jeffrey H BurbankCEOSell10,000$18.31$183,100.00View SEC Filing  
4/8/2015Joseph E Turk JrPresidentSell1,500$18.34$27,510.00View SEC Filing  
3/26/2015Joseph E Turk JrPresidentSell1,150$16.94$19,481.00View SEC Filing  
3/18/2015Jeffrey H BurbankCEOSell20,000$17.40$348,000.00View SEC Filing  
3/10/2015Joseph E Turk JrPresidentSell1,500$16.44$24,660.00View SEC Filing  
2/25/2015Joseph E Turk JrPresidentSell2,082$17.88$37,226.16View SEC Filing  
1/27/2015Joseph E Turk JrPresidentSell2,350$18.70$43,945.00View SEC Filing  
1/14/2015Winifred L SwanSVPSell500$18.44$9,220.00View SEC Filing  
1/13/2015Joseph E Turk JrPresidentSell1,500$18.35$27,525.00View SEC Filing  
1/13/2015Winifred L SwanSVPSell666$18.35$12,221.10View SEC Filing  
12/29/2014Winifred L SwanSVPSell667$18.17$12,119.39View SEC Filing  
12/23/2014Joseph E Turk JrPresidentSell2,350$18.44$43,334.00View SEC Filing  
12/15/2014Joseph E Turk JrPresidentSell2,000$17.45$34,900.00View SEC Filing  
12/15/2014Kevin HershbergerCAOSell8,000$17.19$137,520.00View SEC Filing  
12/10/2014Joseph E Turk JrPresidentSell1,500$17.77$26,655.00View SEC Filing  
12/5/2014Jeffrey H BurbankCEOSell5,000$17.16$85,800.00View SEC Filing  
12/2/2014Robert S BrownInsiderSell34,700$17.44$605,168.00View SEC Filing  
12/1/2014Joseph E Turk JrPresidentSell24,762$17.04$421,944.48View SEC Filing  
12/1/2014Winifred L SwanSVPSell16,667$17.04$284,005.68View SEC Filing  
11/25/2014Joseph E Turk JrPresidentSell3,350$17.59$58,926.50View SEC Filing  
11/14/2014Joseph E Turk JrPresidentSell29,560$17.39$514,048.40View SEC Filing  
11/14/2014Winifred L SwanSVPSell17,167$17.37$298,190.79View SEC Filing  
11/12/2014Joseph E Turk JrPresidentSell26,261$16.27$427,266.47View SEC Filing  
11/12/2014Kevin HershbergerCAOSell11,056$16.58$183,308.48View SEC Filing  
11/7/2014Joseph E Turk JrPresidentSell24,761$16.25$402,366.25View SEC Filing  
11/3/2014Joseph E Turk JrPresidentSell5,717$15.50$88,613.50View SEC Filing  
10/23/2014Joseph E Turk JrPresidentSell3,550$14.55$51,652.50View SEC Filing  
10/23/2014Robert S BrownInsiderSell45,370$14.53$659,226.10View SEC Filing  
9/24/2014Joseph E Turk JrPresidentSell3,550$13.34$47,357.00View SEC Filing  
9/19/2014Jeffrey H BurbankCEOSell2,416$14.00$33,824.00View SEC Filing  
9/19/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
9/10/2014Kevin HershbergerCAOSell843$13.58$11,447.94View SEC Filing  
9/8/2014Jeffrey H BurbankCEOSell2,322$14.00$32,508.00View SEC Filing  
9/8/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
8/27/2014Joseph E Turk JrPresidentSell2,550$13.06$33,303.00View SEC Filing  
8/15/2014Winifred L SwanSVPSell2,500$13.60$34,000.00View SEC Filing  
8/7/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
8/7/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
7/24/2014Joseph E Turk JrPresidentSell3,550$13.50$47,925.00View SEC Filing  
7/18/2014Winifred L SwanSVPSell2,000$13.46$26,920.00View SEC Filing  
6/24/2014Joseph E Turk JrPresidentSell3,950$14.43$56,998.50View SEC Filing  
6/20/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
6/17/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
6/9/2014Winifred L SwanSVPSell9,228$14.00$129,192.00View SEC Filing  
6/5/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
6/5/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
6/5/2014Winifred L SwanSVPSell7,500$14.00$105,000.00View SEC Filing  
5/29/2014Joseph E Turk JrPresidentSell4,035$13.60$54,876.00View SEC Filing  
5/15/2014Winifred SwanSVPSell9,629$12.80$123,251.2021,688View SEC Filing  
5/14/2014Winifred SwanSVPSell5,000$13.04$65,200.0021,688View SEC Filing  
3/6/2014Robert FunariDirectorBuy10,150$14.72$149,408.0010,150View SEC Filing  
10/21/2013Robert S BrownInsiderSell140,100$14.00$1,961,400.00View SEC Filing  
9/9/2013Thomas SheaSVPSell1,000$12.30$12,300.00View SEC Filing  
8/12/2013Thomas SheaSVPSell1,172$12.93$15,153.9611,899View SEC Filing  
7/8/2013Thomas SheaSVPSell7,000$14.34$100,380.00View SEC Filing  
6/10/2013Thomas SheaSVPSell5,000$13.73$68,650.00View SEC Filing  
5/13/2013Thomas SheaSVPSell15,724$12.67$199,223.08View SEC Filing  
11/13/2012David S UtterbergDirectorSell184,204$11.58$2,133,082.32View SEC Filing  
11/2/2012David S UtterbergDirectorSell34,730$11.13$386,544.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NxStage Medical (NASDAQ NXTM) News Headlines

Source:
DateHeadline
NxStage Medical, Inc. (NXTM) SVP Sells $85,680.00 in StockNxStage Medical, Inc. (NXTM) SVP Sells $85,680.00 in Stock
www.americanbankingnews.com - February 22 at 7:08 PM
A Look at NxStage Medical’s Business StrategyA Look at NxStage Medical’s Business Strategy
finance.yahoo.com - February 22 at 5:19 PM
NxStage Medical, Inc. (NXTM) Receives Consensus Rating of "Hold" from AnalystsNxStage Medical, Inc. (NXTM) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 21 at 5:34 PM
NxStage Medical (NXTM) Stock Rating Lowered by BidaskClubNxStage Medical (NXTM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 17 at 10:28 PM
NxStage Medical (NXTM) Rating Lowered to Sell at Zacks Investment ResearchNxStage Medical (NXTM) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 13 at 6:30 AM
$104.45 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter$104.45 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter
www.americanbankingnews.com - February 13 at 1:02 AM
ValuEngine Downgrades NxStage Medical (NXTM) to SellValuEngine Downgrades NxStage Medical (NXTM) to Sell
www.americanbankingnews.com - February 4 at 7:12 PM
Zacks: Brokerages Anticipate NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $104.80 MillionZacks: Brokerages Anticipate NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $104.80 Million
www.americanbankingnews.com - January 28 at 6:58 AM
NxStage Medical, Inc. (NXTM) Receives Average Rating of "Hold" from AnalystsNxStage Medical, Inc. (NXTM) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 27 at 5:34 PM
NxStage Medical (NXTM) Upgraded by Zacks Investment Research to "Hold"NxStage Medical (NXTM) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 26 at 6:08 AM
Winifred L. Swan Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) StockWinifred L. Swan Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) Stock
www.americanbankingnews.com - January 19 at 10:26 PM
This Mornings Technical Outlook on Medical Equipment Stocks -- Nxstage Medical, Nevro, Prestige Brands, and Varian Medical SystemsThis Morning's Technical Outlook on Medical Equipment Stocks -- Nxstage Medical, Nevro, Prestige Brands, and Varian Medical Systems
www.prnewswire.com - January 17 at 10:06 AM
$104.80 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter$104.80 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter
www.americanbankingnews.com - January 10 at 2:42 AM
NxStage Medical (NXTM) Stock Rating Upgraded by Zacks Investment ResearchNxStage Medical (NXTM) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 3 at 2:42 PM
NxStage Medical, Inc. (NXTM) Given Average Rating of "Hold" by AnalystsNxStage Medical, Inc. (NXTM) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 2 at 5:12 PM
NxStage Medical, Inc. (NXTM) Short Interest UpdateNxStage Medical, Inc. (NXTM) Short Interest Update
www.americanbankingnews.com - December 31 at 4:22 AM
ETFs with exposure to NxStage Medical, Inc. : December 26, 2017ETFs with exposure to NxStage Medical, Inc. : December 26, 2017
finance.yahoo.com - December 27 at 2:38 PM
NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:16 PM
Zacks: Brokerages Expect NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 MillionZacks: Brokerages Expect NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 Million
www.americanbankingnews.com - December 25 at 2:26 PM
NxStage Medical, Inc. (NXTM) Expected to Announce Earnings of -$0.01 Per ShareNxStage Medical, Inc. (NXTM) Expected to Announce Earnings of -$0.01 Per Share
www.americanbankingnews.com - December 23 at 1:10 PM
NxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 SharesNxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 Shares
www.americanbankingnews.com - December 21 at 5:52 PM
NxStage Medical under modest pressure on slow pace of acquirer Fresenius to work through U.S. antitrust issues; shares down a fractionNxStage Medical under modest pressure on slow pace of acquirer Fresenius to work through U.S. antitrust issues; shares down a fraction
seekingalpha.com - December 14 at 4:55 PM
NxStage Celebrates Over 5000 Home Hemodialysis Patients Receiving Kidney Transplants - PR Newswire (press release)NxStage Celebrates Over 5000 Home Hemodialysis Patients Receiving Kidney Transplants - PR Newswire (press release)
www.prnewswire.com - December 12 at 5:01 PM
NxStage Celebrates Over 5,000 Home Hemodialysis Patients Receiving Kidney TransplantsNxStage Celebrates Over 5,000 Home Hemodialysis Patients Receiving Kidney Transplants
finance.yahoo.com - December 11 at 10:55 AM
NxStage Medical, Inc. (NXTM) Given Consensus Recommendation of "Hold" by BrokeragesNxStage Medical, Inc. (NXTM) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 8 at 10:00 PM
Nx2me Connected Health® Improves Home Hemodialysis RetentionNx2me Connected Health® Improves Home Hemodialysis Retention
finance.yahoo.com - December 7 at 5:00 PM
NxStage Medical, Inc. (NXTM) Downgraded to Sell at Zacks Investment ResearchNxStage Medical, Inc. (NXTM) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - November 25 at 8:10 PM
NxStage Medical Prepares for Fresenius MergerNxStage Medical Prepares for Fresenius Merger
www.fool.com - November 21 at 1:13 PM
$102.29 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter$102.29 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter
www.americanbankingnews.com - November 19 at 2:54 PM
NxStage Medical, Inc. (NXTM) Expected to Post Quarterly Sales of $102.29 MillionNxStage Medical, Inc. (NXTM) Expected to Post Quarterly Sales of $102.29 Million
www.americanbankingnews.com - November 19 at 2:50 AM
ETFs with exposure to NxStage Medical, Inc. : November 9, 2017ETFs with exposure to NxStage Medical, Inc. : November 9, 2017
finance.yahoo.com - November 12 at 11:14 AM
ETFs with exposure to NxStage Medical, Inc. : November 9, 2017ETFs with exposure to NxStage Medical, Inc. : November 9, 2017
finance.yahoo.com - November 12 at 11:14 AM
NxStage Medical, Inc. (NXTM) Earns Hold Rating from Northland SecuritiesNxStage Medical, Inc. (NXTM) Earns Hold Rating from Northland Securities
www.americanbankingnews.com - November 8 at 3:40 PM
NXTM Crosses Below Key Moving Average LevelNXTM Crosses Below Key Moving Average Level
www.nasdaq.com - November 7 at 4:33 PM
Traders Buy High Volume of NxStage Medical Put Options (NXTM)Traders Buy High Volume of NxStage Medical Put Options (NXTM)
www.americanbankingnews.com - November 6 at 2:28 AM
Eleven Unique NxStage Abstracts Accepted for 2017 Kidney WeekEleven Unique NxStage Abstracts Accepted for 2017 Kidney Week
finance.yahoo.com - November 2 at 7:11 AM
Featured Company News - Shareholders of NxStage Approve Merger with Fresenius Medical CareFeatured Company News - Shareholders of NxStage Approve Merger with Fresenius Medical Care
finance.yahoo.com - October 31 at 7:16 AM
 Brokerages Expect NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 Million Brokerages Expect NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 Million
www.americanbankingnews.com - October 30 at 9:38 AM
NxStage Medical, Inc. (NXTM) Short Interest Down 20.2% in OctoberNxStage Medical, Inc. (NXTM) Short Interest Down 20.2% in October
www.americanbankingnews.com - October 29 at 3:26 AM
Nxstage Medical (NXTM) Stockholders Approve Merger Agreement With Fresenius Medica (FMS) - StreetInsider.comNxstage Medical (NXTM) Stockholders Approve Merger Agreement With Fresenius Medica (FMS) - StreetInsider.com
www.streetinsider.com - October 28 at 3:28 PM
NxStage Announces Stockholder Approval Of Merger Agreement With Fresenius Medical CareNxStage Announces Stockholder Approval Of Merger Agreement With Fresenius Medical Care
finance.yahoo.com - October 28 at 10:35 AM
NxStage Medical, Inc. (NXTM) Set to Announce Quarterly Earnings on WednesdayNxStage Medical, Inc. (NXTM) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 8:02 AM
ETFs with exposure to NxStage Medical, Inc. : October 23, 2017ETFs with exposure to NxStage Medical, Inc. : October 23, 2017
finance.yahoo.com - October 24 at 7:57 AM
NxStage Medical, Inc. (NXTM) SVP Sells $96,250.00 in StockNxStage Medical, Inc. (NXTM) SVP Sells $96,250.00 in Stock
www.americanbankingnews.com - October 23 at 7:46 PM
NxStage Announces Winners of Third Annual Nurse Hero AwardNxStage Announces Winners of Third Annual Nurse Hero Award
finance.yahoo.com - October 19 at 7:01 AM
NxStage Medical, Inc. (NXTM) Rating Reiterated by Canaccord GenuityNxStage Medical, Inc. (NXTM) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - October 17 at 5:16 PM
Zacks: Brokerages Anticipate NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 MillionZacks: Brokerages Anticipate NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 Million
www.americanbankingnews.com - October 11 at 1:54 PM
Zacks Investment Research Downgrades NxStage Medical, Inc. (NXTM) to SellZacks Investment Research Downgrades NxStage Medical, Inc. (NXTM) to Sell
www.americanbankingnews.com - October 10 at 6:56 AM
ETFs with exposure to NxStage Medical, Inc. : October 9, 2017ETFs with exposure to NxStage Medical, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 4:00 PM
NxStage Medical, Inc. breached its 50 day moving average in a Bullish Manner : NXTM-US : October 6, 2017NxStage Medical, Inc. breached its 50 day moving average in a Bullish Manner : NXTM-US : October 6, 2017
finance.yahoo.com - October 7 at 6:47 AM

SEC Filings

NxStage Medical (NASDAQ:NXTM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NxStage Medical (NASDAQ:NXTM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NxStage Medical (NASDAQ NXTM) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.